L3Harris Technologies (LHX) Secures Polish Contract for Viper Shield EW System Upgrade

L3Harris Technologies (LHX) recently secured a contract with Poland to provide the Viper Shield electronic warfare system for its F-16 Viper upgrade program, illustrating confidence in the company's defense solutions. Over the last quarter, LHX’s share price increased by 13%, likely bolstered by this contract alongside other key developments such as business expansions and positive earnings results. This movement aligns with the broader market's upward trajectory, notably as major indexes, including the S&P 500, have marked fresh highs. Thus, the company’s developments likely added momentum to its share price amid an overall market rise.

We've identified 1 possible red flag with L3Harris Technologies and understanding the impact should be part of your investment process.

LHX Earnings Per Share Growth as at Aug 2025
LHX Earnings Per Share Growth as at Aug 2025

Uncover the next big thing with financially sound penny stocks that balance risk and reward.

The recent contract with Poland to supply the Viper Shield electronic warfare system could reinforce L3Harris Technologies' narrative of capturing growth in defense spending both domestically and internationally. This development underscores its position to potentially leverage increased U.S. defense budgets and international demand, which are anticipated to enhance revenue and profit growth. Analysts forecast L3Harris's earnings to reach US$2.7 billion by 2028, supported by ventures like LHX NeXt and collaborations in AI, fostering efficiency and market expansion.

Over the past five years, L3Harris achieved a total shareholder return of 68.34%, reflecting both share price appreciation and dividends. In comparison, its one-year performance trailed the US Aerospace & Defense industry but matched the broader US market, which saw a 17.5% rise. The company's recent share price movement, buoyed by this contract, aligns with analysts' expectations, with a current price of US$276.76 compared to an analyst price target of US$299.95. This represents a modest share price discount to the target, suggesting limited upside according to consensus estimates.

This contract and other recent business expansions might impact the revenue and earnings forecasts positively. However, factors like reliance on external contractors, geopolitical tensions, and fixed-price contract risks could temper growth prospects. With the company's fair valuation near its price target, it's crucial for stakeholders to weigh these elements against their assumptions on its future potential.

Upon reviewing our latest valuation report, L3Harris Technologies' share price might be too pessimistic.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

New: AI Stock Screener & Alerts

Our new AI Stock Screener scans the market every day to uncover opportunities.

• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies

Or build your own from over 50 metrics.

Explore Now for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

About NYSE:LHX

L3Harris Technologies

Provides mission-critical solutions for government and commercial customers worldwide.

Very undervalued established dividend payer.

Similar Companies

Advertisement

Weekly Picks

CE
Ceazar
SPAI logo
Ceazar on Sparc AI ·

When GPS fails: this small cap is fixing a $54B drone problem

Fair Value:CA$5.2554.7% undervalued
108 users have followed this narrative
0 users have commented on this narrative
23 users have liked this narrative
BL
BlackGoat
IREN logo
BlackGoat on IREN ·

IREN's Bold Moves in Sustainable Bitcoin Mining & AI Data Centers

Fair Value:US$71.4859.0% undervalued
213 users have followed this narrative
8 users have commented on this narrative
32 users have liked this narrative
HE
HedgeY
ARM logo
HedgeY on Arm Holdings ·

The Architecture Layer of AI Computing - But Priced Like the Future Already Arrived?

Fair Value:US$43047.7% undervalued
20 users have followed this narrative
1 users have commented on this narrative
6 users have liked this narrative
HI
Hidden_Rock_Capital
FISV logo
Hidden_Rock_Capital on Fiserv ·

Temporary "perfect storm" leads to opportunity to buy financial services leader for less than 5x long-term earnings

Fair Value:US$119.9953.6% undervalued
25 users have followed this narrative
0 users have commented on this narrative
9 users have liked this narrative

Updated Narratives

SI
MSFT logo
simplydunno on Microsoft ·

Microsoft's Capex Bill Comes Due Before the AI Revenue Does

Fair Value:US$512.123.7% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
HE
NGXGROUP logo
Henrynuke03 on Nigerian Exchange Group ·

Future Growth Awaits NGXGROUP with New High-Profile Listings

Fair Value:₦221.1732.3% undervalued
7 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
PR
PrashhD
AURIONPRO logo
PrashhD on Aurionpro Solutions ·

Aurionpro Solutions: Is the Market Mispricing One of India's Most Interesting Fintech Product Companies?

Fair Value:₹1k27.1% undervalued
1 users have followed this narrative
1 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

OS
oscargarcia
NVDA logo
oscargarcia on NVIDIA ·

The company that went from selling GPUs to gamers to becoming the AI arms dealer of the 21st century.

Fair Value:US$28032.1% undervalued
211 users have followed this narrative
9 users have commented on this narrative
15 users have liked this narrative
CU
MSFT logo
CubanEros on Microsoft ·

A wonderful business at reasonable price.

Fair Value:US$419.917.0% undervalued
97 users have followed this narrative
0 users have commented on this narrative
7 users have liked this narrative
BE
PYPL logo
benjamin_lvieq on PayPal Holdings ·

PayPal: PayPal Doesn't Need to Grow – It Needs to Stop Falling – A Mispriced Cash Machine With a Cannibal Buyback

Fair Value:US$6510.2% undervalued
74 users have followed this narrative
2 users have commented on this narrative
11 users have liked this narrative

Trending Discussion

DE
TDOC logo
derek_3wsdg on Teladoc Health ·

You’ve overlooked the activist investor factor. Travis Cocke’s Voss has announced 5% ownership through a 13G filing. They’ve added to that 5% since, and in doing so, have created a structural trap door for 27.42 Million Shares actively sold short. Chuck will announce lots of positives on July 29 but it’s what Voss announces shortly after that will rock the overextended Teledoc shorts. The Walmart partnership is the tip of the iceberg. The market is missing the sheer regulatory and enterprise friction of modern corporate healthcare. Teladoc isn't a "consumer app"; it is the primary digital infrastructure integrated directly into the legacy backends of Tier-1 insurance companies and fortune 500 employers, covering 105 million+ lives. Teladoc is acting as the digital top-of-funnel engine for the world's largest retailer. If Voss pushes the narrative that Teladoc is effectively the outsourced digital brain of Walmart's entire healthcare footprint, the fair value shifts from a basic health multiple to an enterprise distribution premium. Additionally , we are in a structural gold rush for high-quality, legally compliant, longitudinal medical data to train vertical healthcare AI models. Large technology hyperscalers and pharmaceutical giants cannot simply scrape the internet for this; they need structured clinical inputs. Teladoc sits on one of the largest de-identified virtual medical datasets on earth. From the activist playbook , we’ll see Voss demand the immediate creation of a Data & Diagnostics Licensing Division, transforming a legacy liability into an incredibly high-margin, pure-software data asset that requires zero human clinician hours to scale. Chuck is doing great work and deserves credi5 for the Teledoc turnaround but it will be Travis Cocke who will be responsible for a share price way beyond your $15 valuation.

1
|
0
VI
533581 logo
vijay_kant_fobiu on PG Electroplast ·

products

0
|
0